Spelling suggestions: "subject:"pharmacogenetic testing"" "subject:"pharmacogenetics testing""
1 |
What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?06 October 2021 (has links)
Yes / In psychiatry, the selection of antipsychotics and antidepressants is generally led by a trial-and-error approach. The prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions (ADRs). These both contribute to poor levels of adherence. Pharmacogenetics (PGx) considers how genetic variation can influence an individual’s response to a drug. Pharmacogenetic testing is a tool that could aid clinicians when selecting psychotropic medications, as part of a more personalized approach to prescribing. This may improve the use of and adherence to these medications. Yet to date, the implementation of PGx in mental health environments in the United Kingdom has been slow. This review aims to identify the current barriers and enablers to the implementation of PGx in psychiatry and determine how this can be applied to the uptake of PGx by NHS mental health providers. A systematic searching strategy was developed, and searches were carried out on the PsychInfo, EmBase, and PubMed databases, yielding 11 appropriate papers. Common barriers to the implementation of PGx included cost, concerns over incorporation into current workflow and a lack of knowledge about PGx; whilst frequent enablers included optimism that PGx could lead to precision medicine, reduce ADRs and become a more routine part of psychiatric clinical care. The uptake of PGx in psychiatric care settings in the NHS should consider and overcome these barriers, while looking to capitalize on the enablers identified in this review. / Bradford District Care NHS Foundation Trust in partnership with the University of Bradford; National Institute for Health Research (NIHR) Yorkshire and Humber Patient Safety Translational Research Centre (NIHR Yorkshire and Humber PSTRC); National Institute for Health Research Leeds in vitro Diagnostics Co-operative.
|
2 |
Parental Reasons and Reactions toward Return of CYP2D6 Research Results and Perceived Benefits and Harms toward Hypothetical Incidental FindingsAdelsperger, Sarah 19 June 2015 (has links)
No description available.
|
3 |
Pharmakogenetische Untersuchungen beim Hausarzt aus Sicht von Patienten / Patients' perspectives on pharmacogenetic testingPrause, Daniela 23 April 2009 (has links)
No description available.
|
Page generated in 0.1069 seconds